PRO-NAPROXEN DIN 02572184
Health Canada record
| Active ingredient(s) | NAPROXEN 375 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | M01AE02 NAPROXEN |
| Original market date | |
| Current status date | 05-Oct-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pro Doc Limitée — licence 100182, currently licensed, last inspection rating C (2025-08-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing NAPROXEN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02572494 | AG-NAPROXEN | ANGITA PHARMA INC. | Tablet | NAPROXEN 250 MG | Approved |
| 02572508 | AG-NAPROXEN | ANGITA PHARMA INC. | Tablet | NAPROXEN 375 MG | Approved |
| 02572516 | AG-NAPROXEN | ANGITA PHARMA INC. | Tablet | NAPROXEN 500 MG | Approved |
| 00600806 | APO-NAPROXEN | APOTEX INC | Tablet | NAPROXEN 375 MG | Marketed |
| 00522651 | APO-NAPROXEN | APOTEX INC | Tablet | NAPROXEN 250 MG | Marketed |
| 00592277 | APO-NAPROXEN | APOTEX INC | Tablet | NAPROXEN 500 MG | Marketed |
| 02564548 | APO-NAPROXEN / ESOMEPRAZOLE | APOTEX INC | Tablet (Immediate- And Delayed-Release) | NAPROXEN 500 MG; ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE) 20 MG | Marketed |
| 02564521 | APO-NAPROXEN / ESOMEPRAZOLE | APOTEX INC | Tablet (Immediate- And Delayed-Release) | NAPROXEN 375 MG; ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE) 20 MG | Marketed |
| 02246701 | APO-NAPROXEN EC | APOTEX INC | Tablet (Enteric-Coated) | NAPROXEN 500 MG | Marketed |
| 02246700 | APO-NAPROXEN EC | APOTEX INC | Tablet (Enteric-Coated) | NAPROXEN 375 MG | Marketed |
| 02246699 | APO-NAPROXEN EC TABLETS | APOTEX INC | Tablet (Enteric-Coated) | NAPROXEN 250 MG | Marketed |
| 02568551 | JAMP NAPROXEN | JAMP PHARMA CORPORATION | Tablet | NAPROXEN 500 MG | Approved |
| 02568543 | JAMP NAPROXEN | JAMP PHARMA CORPORATION | Tablet | NAPROXEN 375 MG | Approved |
| 02568535 | JAMP NAPROXEN | JAMP PHARMA CORPORATION | Tablet | NAPROXEN 250 MG | Approved |
| 02443449 | MYLAN-NAPROXEN/ESOMEPRAZOLE MR | MYLAN PHARMACEUTICALS ULC | Tablet (Immediate- And Delayed-Release) | NAPROXEN 500 MG; ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE) 20 MG | Marketed |
| 02458608 | MYLAN-NAPROXEN/ESOMEPRAZOLE MR | MYLAN PHARMACEUTICALS ULC | Tablet (Immediate- And Delayed-Release) | NAPROXEN 375 MG; ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE) 20 MG | Marketed |
| 02162466 | NAPROSYN | SEARCHLIGHT PHARMA INC | Tablet (Extended-Release) | NAPROXEN 750 MG | Marketed |
| 02162423 | NAPROSYN | SEARCHLIGHT PHARMA INC | Tablet (Delayed-Release) | NAPROXEN 500 MG | Marketed |
| 02162431 | PEDIAPHARM NAPROXEN SUSPENSION | MEDEXUS PHARMACEUTICALS INC. | Suspension | NAPROXEN 25 MG | Marketed |
| 02572176 | PRO-NAPROXEN | PRO DOC LIMITEE | Tablet | NAPROXEN 250 MG | Approved |
| 02572192 | PRO-NAPROXEN | PRO DOC LIMITEE | Tablet | NAPROXEN 500 MG | Approved |
| 02310953 | PRO-NAPROXEN EC | PRO DOC LIMITEE | Tablet (Delayed-Release) | NAPROXEN 500 MG | Marketed |
| 02572141 | PRO-NAPROXEN EC | PRO DOC LIMITEE | Tablet (Delayed-Release) | NAPROXEN 250 MG | Approved |
| 02572168 | PRO-NAPROXEN EC | PRO DOC LIMITEE | Tablet (Delayed-Release) | NAPROXEN 375 MG | Approved |
| 00565350 | TEVA-NAPROXEN | TEVA CANADA LIMITED | Tablet | NAPROXEN 250 MG | Marketed |
| 00589861 | TEVA-NAPROXEN | TEVA CANADA LIMITED | Tablet | NAPROXEN 500 MG | Marketed |
| 00627097 | TEVA-NAPROXEN | TEVA CANADA LIMITED | Tablet | NAPROXEN 375 MG | Marketed |
| 02243313 | TEVA-NAPROXEN EC | TEVA CANADA LIMITED | Tablet (Enteric-Coated) | NAPROXEN 375 MG | Marketed |
| 02243312 | TEVA-NAPROXEN EC | TEVA CANADA LIMITED | Tablet (Enteric-Coated) | NAPROXEN 250 MG | Marketed |
| 02243314 | TEVA-NAPROXEN EC | TEVA CANADA LIMITED | Tablet (Enteric-Coated) | NAPROXEN 500 MG | Marketed |
| 02361728 | VIMOVO | XEDITON PHARMACEUTICALS INC | Tablet (Immediate- And Delayed-Release) | NAPROXEN 500 MG; ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE) 20 MG | Marketed |
| 02361701 | VIMOVO | XEDITON PHARMACEUTICALS INC | Tablet (Immediate- And Delayed-Release) | NAPROXEN 375 MG; ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM TRIHYDRATE) 20 MG | Marketed |
| 02463687 | WAYMADE-NAPROXEN | WAYMADE PLC | Tablet (Enteric-Coated) | NAPROXEN 500 MG | Approved |
| 02463679 | WAYMADE-NAPROXEN | WAYMADE PLC | Tablet (Enteric-Coated) | NAPROXEN 375 MG | Approved |
| 00522678 | APO NAPROXEN TAB 125MG | APOTEX INC | Tablet | NAPROXEN 125 MG | Dormant |
| 02365863 | AVA-NAPROXEN EC | AVANSTRA INC | Tablet (Enteric-Coated) | NAPROXEN 500 MG | Cancelled Post Market |
| 02365847 | AVA-NAPROXEN EC | AVANSTRA INC | Tablet (Enteric-Coated) | NAPROXEN 250 MG | Cancelled Post Market |
| 02243432 | MYLAN-NAPROXEN EC | MYLAN PHARMACEUTICALS ULC | Tablet (Enteric-Coated) | NAPROXEN 375 MG | Cancelled Post Market |
| 00335193 | NAPROSYN 250MG | SYNTEX INC. | Tablet | NAPROXEN 250 MG | Cancelled Post Market |
| 00583367 | NAPROSYN 375MG | SYNTEX INC. | Tablet | NAPROXEN 375 MG | Cancelled Post Market |
| 00587923 | NAPROSYN SUS 25MG/ML | SYNTEX INC. | Suspension | NAPROXEN 25 MG | Cancelled Post Market |
| 00788767 | NAPROSYN-SR TAB 750MG | SYNTEX INC. | Tablet (Extended-Release) | NAPROXEN 750 MG | Cancelled Post Market |
| 02350750 | NAPROXEN | SANIS HEALTH INC | Tablet | NAPROXEN 250 MG | Cancelled Post Market |
| 02350769 | NAPROXEN | SANIS HEALTH INC | Tablet | NAPROXEN 375 MG | Cancelled Post Market |
| 02350777 | NAPROXEN | SANIS HEALTH INC | Tablet | NAPROXEN 500 MG | Cancelled Post Market |
| 00590762 | NAPROXEN - 250 | PRO DOC LIMITEE | Tablet | NAPROXEN 250 MG | Cancelled Post Market |
| 00590754 | NAPROXEN 125 TAB 125MG | PRO DOC LIMITEE | Tablet | NAPROXEN 125 MG | Cancelled Post Market |
| 02350793 | NAPROXEN EC | SANIS HEALTH INC | Tablet (Enteric-Coated) | NAPROXEN 375 MG | Cancelled Post Market |
| 00565369 | NOVO-NAPROX TAB 125MG | NOVOPHARM LIMITED | Tablet | NAPROXEN 125 MG | Cancelled Post Market |
| 02346605 | NTP-NAPROXEN | TEVA CANADA LIMITED | Tablet | NAPROXEN 500 MG | Cancelled Pre Market |
| 02346591 | NTP-NAPROXEN | TEVA CANADA LIMITED | Tablet | NAPROXEN 375 MG | Cancelled Pre Market |
| 02346621 | NTP-NAPROXEN EC | TEVA CANADA LIMITED | Tablet (Enteric-Coated) | NAPROXEN 375 MG | Cancelled Pre Market |
| 02346613 | NTP-NAPROXEN EC | TEVA CANADA LIMITED | Tablet (Enteric-Coated) | NAPROXEN 250 MG | Cancelled Pre Market |
| 02336588 | NU-NAPROX EC | NU-PHARM INC | Tablet (Enteric-Coated) | NAPROXEN 500 MG | Cancelled (Unreturned Annual) |
| 02336561 | NU-NAPROX EC | NU-PHARM INC | Tablet (Enteric-Coated) | NAPROXEN 375 MG | Cancelled (Unreturned Annual) |
| 00865621 | NU-NAPROX TAB 125MG | NU-PHARM INC | Tablet | NAPROXEN 125 MG | Cancelled Post Market |
| 02294702 | PMS-NAPROXEN EC | PHARMASCIENCE INC | Tablet (Enteric-Coated) | NAPROXEN 375 MG | Cancelled Post Market |
| 02294710 | PMS-NAPROXEN EC | PHARMASCIENCE INC | Tablet (Enteric-Coated) | NAPROXEN 500 MG | Cancelled Post Market |
| 00615331 | RATIO-NAPROXEN | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | Tablet | NAPROXEN 500 MG | Cancelled Post Market |
| 02240788 | RIVA-NAPROXEN | LABORATOIRE RIVA INC. | Tablet | NAPROXEN 500 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 38409 | 2026-10-05 | Supplement to a New Drug Submission (SNDS) | Administrative: Licensing Agreement between two manufacturers |
International API supply for NAPROXEN
7 valid EDQM Certificates of Suitability from 6 holders. 19 active FDA Drug Master Files.
Request a quote for PRO-NAPROXEN